Coya Therapeutics, Inc. (COYA)

NCM – Real Time Price. Currency in USD

4.29

+0.11 (2.63%)

At close: May 12, 2026, 4:00 PM EDT

4.29

-0.00 (-0.04%)

After-hours: May 12, 2026, 7:33 PM EDT

09.04.2026

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal measurement of well-characterized serum biomarkers of lipid peroxidation (4-hydroxy-2-nonenal [4-HNE]), systemic inflammation (lipopolys.

02.04.2026

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that founder Howard Berman, Ph.D., has stepped down as Executive Chairman and as a member of the Board, and that Mark H. Pavao has been appointed to the Board as an independent director. Dr. Berman became Executive Chairman in November 2024 a.

18.03.2026

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD). The study has been published in the pee.

16.03.2026

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the year ended December 31, 2025. Corporate Highlights FY 2025 to Date COYA 302 Successfully launched the ALSTARS Phase 2 trial evaluating COYA 302 for the treatment of ALS and now actively.

25.02.2026

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10.02.2026

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape. Titled ‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress', the webinar will explore re.

30.01.2026

Coya Therapeutics Announces $11.1 Million Private Placement

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte.

Videos

No Data

There is no data to display

Press releases

09.04.2026

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

02.04.2026

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that founder Howard Berman, Ph.D., has stepped down as Executive Chairman and as a member of the Board, and that Mark H. Pavao has been appointed to the Board as an independent director. Dr. Berman became Executive Chairman in November 2024 a.

18.03.2026

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD). The study has been published in the pee.

16.03.2026

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the year ended December 31, 2025. Corporate Highlights FY 2025 to Date COYA 302 Successfully launched the ALSTARS Phase 2 trial evaluating COYA 302 for the treatment of ALS and now actively.

Coya Therapeutics, Inc. (COYA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics Announces $11.1 Million Private Placement

Videos

No Data

Press releases

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics Announces $11.1 Million Private Placement

Videos

No Data

Press releases

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Search stocks

Coya Therapeutics, Inc. (COYA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics Announces $11.1 Million Private Placement

Videos

No Data

Press releases

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics Announces $11.1 Million Private Placement

Videos

No Data

Press releases

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results